SK78598A3 - Complementary adenoviral vector systems and cell lines - Google Patents

Complementary adenoviral vector systems and cell lines Download PDF

Info

Publication number: SK78598A3
Authority: SK; Slovakia
Prior art keywords: adenoviral vector; adenoviral; vector; region; genome
Prior art date: 1995-12-14

Application number

SK785-98A

Other languages

English (en)

Slovak (sk)

Inventor

Imre Kovesdi

Douglas E Brough

Duncan L Mcvey

Joseph T Bruder

Alena Lizonova

Original Assignee

Genvec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-14

Filing date

1996-12-12

Publication date

1998-12-02

1996-12-12 Application filed by Genvec Inc filed Critical Genvec Inc

1998-12-02 Publication of SK78598A3 publication Critical patent/SK78598A3/sk

Links

239000013598 vector Substances 0.000 title claims abstract description 277
230000000295 complement effect Effects 0.000 title claims description 44
230000002950 deficient Effects 0.000 claims abstract description 138
230000010076 replication Effects 0.000 claims abstract description 59
238000000034 method Methods 0.000 claims abstract description 32
108090000623 proteins and genes Proteins 0.000 claims description 114
230000014509 gene expression Effects 0.000 claims description 89
241000700605 Viruses Species 0.000 claims description 82
241000701161 unidentified adenovirus Species 0.000 claims description 55
230000012010 growth Effects 0.000 claims description 43
230000006870 function Effects 0.000 claims description 35
230000008488 polyadenylation Effects 0.000 claims description 19
108700026244 Open Reading Frames Proteins 0.000 claims description 18
229920001184 polypeptide Polymers 0.000 claims description 17
108090000765 processed proteins & peptides Proteins 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
230000006798 recombination Effects 0.000 claims description 11
238000005215 recombination Methods 0.000 claims description 11
230000007812 deficiency Effects 0.000 claims description 9
102000004169 proteins and genes Human genes 0.000 claims description 9
108700039887 Essential Genes Proteins 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
230000001988 toxicity Effects 0.000 claims description 5
231100000419 toxicity Toxicity 0.000 claims description 5
108700005075 Regulator Genes Proteins 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 3
230000028993 immune response Effects 0.000 claims description 3
108020005544 Antisense RNA Proteins 0.000 claims description 2
239000003184 complementary RNA Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
230000001737 promoting effect Effects 0.000 claims 2
238000012239 gene modification Methods 0.000 claims 1
230000001902 propagating effect Effects 0.000 claims 1
238000010998 test method Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
238000001415 gene therapy Methods 0.000 abstract description 20
125000006850 spacer group Chemical group 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 205
108020004414 DNA Proteins 0.000 description 71
230000037430 deletion Effects 0.000 description 71
238000012217 deletion Methods 0.000 description 71
239000012634 fragment Substances 0.000 description 60
102000052510 DNA-Binding Proteins Human genes 0.000 description 37
239000013612 plasmid Substances 0.000 description 36
101710096438 DNA-binding protein Proteins 0.000 description 35
238000004519 manufacturing process Methods 0.000 description 35
230000003612 virological effect Effects 0.000 description 34
108091008146 restriction endonucleases Proteins 0.000 description 28
101710087110 ORF6 protein Proteins 0.000 description 19
101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 19
239000002773 nucleotide Substances 0.000 description 19
125000003729 nucleotide group Chemical class 0.000 description 19
239000000835 fiber Substances 0.000 description 18
239000013603 viral vector Substances 0.000 description 18
208000015181 infectious disease Diseases 0.000 description 17
108091028043 Nucleic acid sequence Proteins 0.000 description 16
210000000234 capsid Anatomy 0.000 description 14
238000010586 diagram Methods 0.000 description 13
238000003119 immunoblot Methods 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 13
101710145505 Fiber protein Proteins 0.000 description 12
230000000694 effects Effects 0.000 description 12
102000039446 nucleic acids Human genes 0.000 description 12
108020004707 nucleic acids Proteins 0.000 description 12
150000007523 nucleic acids Chemical class 0.000 description 12
238000003752 polymerase chain reaction Methods 0.000 description 12
108020005202 Viral DNA Proteins 0.000 description 11
230000001939 inductive effect Effects 0.000 description 11
101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 10
101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 10
230000004543 DNA replication Effects 0.000 description 10
101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 10
101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 10
238000009472 formulation Methods 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
238000003780 insertion Methods 0.000 description 10
239000006166 lysate Substances 0.000 description 10
102000053187 Glucuronidase Human genes 0.000 description 9
108010060309 Glucuronidase Proteins 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000002245 particle Substances 0.000 description 9
238000001890 transfection Methods 0.000 description 9
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000010276 construction Methods 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
230000014616 translation Effects 0.000 description 8
239000002609 medium Substances 0.000 description 7
238000010369 molecular cloning Methods 0.000 description 7
108091026890 Coding region Proteins 0.000 description 6
102000004594 DNA Polymerase I Human genes 0.000 description 6
108010017826 DNA Polymerase I Proteins 0.000 description 6
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000003550 marker Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
238000002255 vaccination Methods 0.000 description 6
102000053602 DNA Human genes 0.000 description 5
241000282412 Homo Species 0.000 description 5
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000027455 binding Effects 0.000 description 5
239000013592 cell lysate Substances 0.000 description 5
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
238000013519 translation Methods 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
108010086093 Mung Bean Nuclease Proteins 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
239000001506 calcium phosphate Substances 0.000 description 4
229910000389 calcium phosphate Inorganic materials 0.000 description 4
235000011010 calcium phosphates Nutrition 0.000 description 4
230000008859 change Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
229960005542 ethidium bromide Drugs 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
230000007505 plaque formation Effects 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
208000010370 Adenoviridae Infections Diseases 0.000 description 3
101150029409 CFTR gene Proteins 0.000 description 3
241000557626 Corvus corax Species 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
101150005585 E3 gene Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
101001049954 Human adenovirus C serotype 2 Early 4 ORF6 protein Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229930193140 Neomycin Natural products 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
ZJBMQVPEJHVSQA-OCYVVMCSSA-N Pyrromycin Chemical compound O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 ZJBMQVPEJHVSQA-OCYVVMCSSA-N 0.000 description 3
101710172711 Structural protein Proteins 0.000 description 3
241000030538 Thecla Species 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000007380 fibre production Methods 0.000 description 3
230000009643 growth defect Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
229960004927 neomycin Drugs 0.000 description 3
230000008569 process Effects 0.000 description 3
229950010131 puromycin Drugs 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
206010001258 Adenoviral infections Diseases 0.000 description 2
241000701242 Adenoviridae Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
101710116602 DNA-Binding protein G5P Proteins 0.000 description 2
241000710188 Encephalomyocarditis virus Species 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
101150007210 ORF6 gene Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
101710162453 Replication factor A Proteins 0.000 description 2
101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 2
101710176276 SSB protein Proteins 0.000 description 2
101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
210000002534 adenoid Anatomy 0.000 description 2
108700010877 adenoviridae proteins Proteins 0.000 description 2
238000010170 biological method Methods 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
239000000872 buffer Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
108091092356 cellular DNA Proteins 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000010432 diamond Substances 0.000 description 2
102000004419 dihydrofolate reductase Human genes 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000001163 endosome Anatomy 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
230000030648 nucleus localization Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000001124 posttranscriptional effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002356 single layer Substances 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000009447 viral pathogenesis Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
241000321096 Adenoides Species 0.000 description 1
108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
206010060931 Adenovirus infection Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
101100191372 Arabidopsis thaliana PRK5 gene Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000701802 Aviadenovirus Species 0.000 description 1
101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
101150012716 CDK1 gene Proteins 0.000 description 1
101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 1
101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 1
101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
102000005853 Clathrin Human genes 0.000 description 1
108010019874 Clathrin Proteins 0.000 description 1
101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
101150091887 Ctla4 gene Proteins 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
102000003909 Cyclin E Human genes 0.000 description 1
108090000257 Cyclin E Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
101150026402 DBP gene Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101150066038 E4 gene Proteins 0.000 description 1
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
101710183861 Hexon-associated protein Proteins 0.000 description 1
101710155188 Hexon-interlacing protein Proteins 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
241000598171 Human adenovirus sp. Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
101100353036 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pme-1 gene Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108010047956 Nucleosomes Proteins 0.000 description 1
101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
102100033254 Tumor suppressor ARF Human genes 0.000 description 1
101710102803 Tumor suppressor ARF Proteins 0.000 description 1
101710183681 Uncharacterized protein 7 Proteins 0.000 description 1
101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000011589 adenoviridae infectious disease Diseases 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
244000309466 calf Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229930193282 clathrin Natural products 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000012136 culture method Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000000531 effect on virus Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
230000006658 host protein synthesis Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000004492 nuclear pore Anatomy 0.000 description 1
210000001623 nucleosome Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
101150059999 pro gene Proteins 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
108091005974 protein filaments Proteins 0.000 description 1
102000034272 protein filaments Human genes 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001533 respiratory mucosa Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000010257 thawing Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000004095 viral genome expression Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000010464 virion assembly Effects 0.000 description 1
238000003466 welding Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000009614 wildtype growth Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Veterinary Medicine (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Design And Manufacture Of Integrated Circuits (AREA)
Semiconductor Memories (AREA)

SK785-98A 1995-12-14 1996-12-12 Complementary adenoviral vector systems and cell lines SK78598A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/572,126 US5851806A (en)	1994-06-10	1995-12-14	Complementary adenoviral systems and cell lines
PCT/US1996/019839 WO1997021826A2 (en)	1995-12-14	1996-12-12	Complementary adenoviral vector systems and cell lines

Publications (1)

Publication Number	Publication Date
SK78598A3 true SK78598A3 (en)	1998-12-02

Family

ID=24286453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK785-98A SK78598A3 (en)	1995-12-14	1996-12-12	Complementary adenoviral vector systems and cell lines

Country Status (21)

Country	Link
US (1)	US5851806A (de)
EP (1)	EP0870049B1 (de)
JP (2)	JP3299761B2 (de)
AT (1)	ATE320503T1 (de)
AU (1)	AU711366B2 (de)
BG (1)	BG62739B1 (de)
BR (1)	BR9612677A (de)
CA (1)	CA2238295C (de)
CZ (1)	CZ182798A3 (de)
DE (1)	DE69635931T2 (de)
EA (1)	EA199800566A1 (de)
EE (1)	EE9800185A (de)
GE (1)	GEP20012559B (de)
HU (1)	HUP9902310A3 (de)
IL (1)	IL124797A0 (de)
IS (1)	IS4762A (de)
NO (1)	NO982687L (de)
NZ (1)	NZ325627A (de)
PL (1)	PL327984A1 (de)
SK (1)	SK78598A3 (de)
WO (1)	WO1997021826A2 (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2192442C (en) *	1994-06-10	2007-09-25	Imre Kovesdi	Complementary adenoviral vector systems and cell lines
US20030148968A1 (en) *	1995-02-28	2003-08-07	Hammond H. Kirk	Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
WO1996026742A1 (en)	1995-02-28	1996-09-06	The Regents Of The University Of California	Gene transfer-mediated angiogenesis therapy
US6281010B1 (en) *	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
KR100470180B1 (ko) *	1995-06-15	2005-02-04	크루셀 홀란드 비.브이.	유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6783980B2 (en) *	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) *	1995-06-15	2001-07-24	Introgene B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030027250A1 (en) *	1995-12-15	2003-02-06	Mitchell Lloyd G.	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) *	1995-12-15	2002-12-19	Mitchell Lloyd G.	Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) *	1995-12-15	2006-04-27	Mitchell Lloyd G	Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
EP0937150A2 (de) *	1996-09-25	1999-08-25	Novartis AG	Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
US7232899B2 (en)	1996-09-25	2007-06-19	The Scripps Research Institute	Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
CA2278621A1 (en) *	1997-01-29	1998-07-30	Cornell Research Foundation, Inc.	Multiple site delivery of adenoviral vector for the induction of angiogenesis
US6706693B1 (en)	1997-08-13	2004-03-16	The Uab Research Foundation	Vaccination by topical application of genetic vectors
US6716823B1 (en)	1997-08-13	2004-04-06	The Uab Research Foundation	Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) *	1997-08-13	2002-02-19	The Uab Research Foundation	Noninvasive genetic immunization, expression products therefrom and uses thereof
US6696423B1 (en)	1997-08-29	2004-02-24	Biogen, Inc.	Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CA2340276A1 (en)	1998-08-28	2000-03-09	Duke University	Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
US6303362B1 (en) *	1998-11-19	2001-10-16	The Board Of Trustees Of The Leland Stanford Junior University	Adenoviral vector and methods for making and using the same
CA2371069A1 (en) *	1999-04-23	2001-02-01	Crucell Holland B.V.	Means and methods for nucleic acid transfer
US20040009936A1 (en) *	1999-05-03	2004-01-15	Tang De-Chu C.	Vaccine and drug delivery by topical application of vectors and vector extracts
US6793926B1 (en)	1999-05-27	2004-09-21	Genovo, Inc.	Methods for production of a recombinant adeno-associated virus
US6627190B2 (en) *	1999-07-12	2003-09-30	Saint Louis University	Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6613516B1 (en) *	1999-10-30	2003-09-02	Affymetrix, Inc.	Preparation of nucleic acid samples
US6867022B1 (en)	2000-01-21	2005-03-15	Regents Of The University Of Michigan	Replication deficient adenovirus vectors and methods of making and using them
US6821775B1 (en) *	2000-02-11	2004-11-23	Genvec, Inc.	Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) *	2006-12-14	2010-01-26	International Business Machines Corporation	Management of devices connected to infiniband ports
US6591543B2 (en) *	2000-04-14	2003-07-15	Kenneth P. Sabine	Top water lure with highly active propeller
CN1293196C (zh)	2000-05-26	2007-01-03	大日本住友制药株式会社	具有副作用降低的特性的新型重组腺病毒载体
US6579522B1 (en) *	2000-06-27	2003-06-17	Genvec, Inc.	Replication deficient adenoviral TNF vector
EP1203819A3 (de) *	2000-10-06	2002-08-07	Transgene S.A.	Entzündungshemmende Vektoren
US6573092B1 (en) *	2000-10-10	2003-06-03	Genvec, Inc.	Method of preparing a eukaryotic viral vector
US20040126774A1 (en) *	2001-01-08	2004-07-01	Mitchell Lioyd G.	Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
EP1427816A4 (de)	2001-09-18	2004-12-01	Clontech Lab Inc	Auf stellenspezifischer rekombinase beruhendes verfahren zur herstellung von adenovirusvektoren
US20030086903A1 (en) *	2001-11-02	2003-05-08	Genvec, Inc.	Therapeutic regimen for treating cancer
US20030087438A1 (en) *	2001-11-02	2003-05-08	Genvec, Inc.	E1-revertant-free adenoviral composition
US20030158112A1 (en) *	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
US7399753B2 (en) *	2002-02-25	2008-07-15	Virxsys Corporation	Trans-splicing mediated photodynamic therapy
US7094399B2 (en) *	2002-05-08	2006-08-22	Intronn, Inc.	Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses
EP1579004B1 (de) *	2002-10-23	2010-06-16	VIRxSYS Corporation	Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
AU2003297607A1 (en) *	2002-12-02	2004-06-23	Genvec, Inc	Materials and methods for treating ocular-related disorders
US20040166091A1 (en)	2003-02-24	2004-08-26	Genvec, Inc.	Materials and methods for treating disorders of the ear
EP1606313A2 (de) *	2003-03-19	2005-12-21	Isogenis, Inc.	Spezifische hemmung der abstossreaktion bei allotransplantaten
ES2391975T3 (es) *	2003-07-25	2012-12-03	Genvec, Inc.	Vacunas a base de vector adenovírico
EP2168603A1 (de)	2003-11-14	2010-03-31	GenVec, Inc.	Therapeutisches Programm zur Behandlung von Krebs
NZ546983A (en) *	2003-11-24	2009-05-31	Canji Inc	Reduction of dermal scarring
AU2005207053A1 (en) *	2004-01-23	2005-08-04	Virxsys Corporation	Expression of ApoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
WO2005070948A1 (en)	2004-01-23	2005-08-04	Intronn, Inc.	Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
US7968334B2 (en) *	2004-01-23	2011-06-28	Virxsys Corporation	Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
ES2329607T3 (es) *	2004-02-23	2009-11-27	Crucell Holland B.V.	Metodos de purificacion de virus.
WO2005089811A1 (en) *	2004-03-12	2005-09-29	Genvec, Inc.	Materials for treating vascular leakage in the eye
JP2007532656A (ja)	2004-04-12	2007-11-15	アメリカ合衆国	アデノウイルスベクターを用いて免疫応答を誘導するための方法
JP2008507282A (ja) *	2004-07-20	2008-03-13	アイソジェニス・インコーポレイテッド	自己免疫および自己抗原に関連する疾患の特異的阻害
US20060094110A1 (en) *	2004-07-30	2006-05-04	Mcgarrity Gerard J	Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) *	2004-08-09	2006-06-22	Garcia-Blanco Mariano A	Use of RNA trans-splicing for generation of interfering RNA molecules
JP2008511336A (ja) *	2004-09-01	2008-04-17	アメリカ合衆国	免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
DE102004047492B4 (de) *	2004-09-23	2006-07-20	Jost-Werke Gmbh & Co. Kg	Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
AU2005326784B2 (en) *	2004-10-08	2012-03-15	Virxsys Corporation	Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
US7871795B2 (en)	2004-10-08	2011-01-18	Virxsys Corporation	Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US20060188481A1 (en) *	2005-02-22	2006-08-24	Saitama Medical School	Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
US7524510B2 (en)	2005-02-23	2009-04-28	The Uab Research Foundation	Alkyl-glycoside enhanced vaccination
US8574595B2 (en) *	2005-04-11	2013-11-05	Crucell Holland B.V.	Virus purification using ultrafiltration
US8450055B2 (en) *	2005-08-31	2013-05-28	The United States Of America As Represented By The Secretary Of The Navy	Malaria antigen screening method
AU2006284756B2 (en) *	2005-08-31	2012-06-07	Genvec, Inc.	Adenoviral vector-based malaria vaccines
US9651543B2 (en)	2005-08-31	2017-05-16	The United States Of America As Represented By The Secretary Of The Navy	Malaria antigen screening method
CA2629163C (en) *	2005-11-10	2017-03-21	Genvec, Inc.	Adenoviral vector-based foot-and-mouth disease vaccine
US20080248060A1 (en) *	2007-01-09	2008-10-09	Genvec, Inc.	Adenoviral vector-based malaria vaccines
WO2008112540A2 (en) *	2007-03-09	2008-09-18	Vectorlogics, Inc.	Cells for adenovirus vector and protein production
US20100263066A1 (en) *	2007-04-30	2010-10-14	Medtronic, Inc	Inert dna sequences for efficient viral packaging and methods of use
US20090202492A1 (en) *	2008-01-25	2009-08-13	University Of South Florida	Adenovirus vaccine utilizing ikk as adjuvant
WO2010033722A2 (en)	2008-09-17	2010-03-25	Isogenis, Inc.	Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
WO2010060719A1 (en)	2008-11-03	2010-06-03	Crucell Holland B.V.	Method for the production of adenoviral vectors
PL2488636T3 (pl)	2009-10-15	2014-07-31	Crucell Holland Bv	Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym
CN102575233B (zh)	2009-10-15	2014-07-16	克鲁塞尔荷兰公司	从高细胞密度培养物纯化腺病毒的方法
US20120219583A1 (en)	2009-10-16	2012-08-30	Los Alamos National Security, Llc	Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en)	2009-11-09	2011-05-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Simian adenoviral vector-based vaccines
PH12012500908A1 (en)	2009-11-09	2017-08-23	Genvec Inc	Methods of propagating monkey adenoviral vectors
KR101820980B1 (ko)	2010-02-15	2018-01-22	얀센 백신스 앤드 프리벤션 비.브이.	Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
EP2547362B1 (de)	2010-03-17	2021-08-25	Cornell University	Unterbrochener impfstoff auf adenovirusbasis gegen drogenmissbrauch
US20130195800A1 (en)	2010-03-23	2013-08-01	Intrexon Corporation	Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
WO2012021730A2 (en)	2010-08-11	2012-02-16	Genvec, Inc.	Respiratory syncytial virus (rsv) vaccine
CN103118702A (zh)	2010-09-20	2013-05-22	克鲁塞尔荷兰公司	活动性结核病的治疗性接种
MX354752B (es)	2010-09-27	2018-03-20	Janssen Vaccines & Prevention Bv	Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
WO2012083297A2 (en)	2010-12-17	2012-06-21	Genvec, Inc.	Adenoviral vectors with modified hexon regions
WO2012088041A1 (en)	2010-12-20	2012-06-28	Genvec, Inc.	Adenoviral vector-based dengue fever vaccine
US9402919B2 (en)	2011-03-04	2016-08-02	Intrexon Corporation	Vectors conditionally expressing protein
WO2012162428A1 (en)	2011-05-23	2012-11-29	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prime-boost vaccination for viral infection
CN107937440A (zh)	2011-10-05	2018-04-20	金维克有限公司	猴腺病毒(大猩猩)或腺病毒载体及其使用方法
BR112014008167B1 (pt)	2011-10-05	2022-05-24	Genvec Inc	Adenovírus ou vetor adenoviral e composição os compreendendo
EP2764014B1 (de)	2011-10-05	2022-02-09	GenVec, Inc.	Adenovirusvektoren und verwendungsverfahren dafür
EP2764011B1 (de)	2011-10-05	2021-04-07	GenVec, Inc.	Auf adenovirenvektoren-basierender impfstoff gegen das respiratorische synzytialvirus (rsv)
US20130122038A1 (en)	2011-11-14	2013-05-16	The United States Of America As Represented By The Secretary Of The Department	Heterologous prime-boost immunization using measles virus-based vaccines
EP2809346A1 (de)	2012-02-02	2014-12-10	GenVec, Inc.	Auf adenoviralen vektoren basierender malaria-impfstoff
SI2825640T1 (sl)	2012-03-12	2016-08-31	Crucell Holland B.V.	Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
MY169352A (en)	2012-03-22	2019-03-25	Janssen Vaccines & Prevention Bv	Vaccine against rsv
US9125870B2 (en)	2012-03-22	2015-09-08	Crucell Holland B.V.	Vaccine against RSV
WO2013181128A1 (en)	2012-05-29	2013-12-05	Genvec, Inc.	Modified serotype 28 adenoviral vectors
WO2013180967A1 (en)	2012-05-29	2013-12-05	Genvec, Inc.	Herpes simplex virus vaccine
PT2970398T (pt)	2013-03-13	2024-06-07	The Us Secretary Department Ofhealth And Human Servic	Proteínas f de pré-fusão do vsr e sua utilização
AU2014259474B2 (en)	2013-04-25	2018-09-13	Janssen Vaccines & Prevention B.V.	Stabilized soluble prefusion RSV F polypeptides
CN105408348B (zh)	2013-06-17	2021-07-06	扬森疫苗与预防公司	稳定化的可溶性融合前rsv f多肽
CN105530917B (zh)	2013-09-19	2020-06-05	扬森疫苗与预防公司	改进的腺病毒配制品
WO2016037154A1 (en)	2014-09-04	2016-03-10	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Recombinant hiv-1 envelope proteins and their use
TWI710635B (zh) *	2014-10-09	2020-11-21	美商珍維克公司	編碼人類無調同源物-1(hath1)之腺病毒載體
AU2015341926B2 (en)	2014-11-04	2018-09-27	Vidamune B.V.	Therapeutic HPV16 vaccines
US10420834B2 (en)	2014-12-24	2019-09-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant metapneumovirus F proteins and their use
ES3058017T3 (en)	2015-01-20	2026-03-06	Us Health	Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
US10301377B2 (en)	2015-02-24	2019-05-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016146844A1 (en)	2015-03-18	2016-09-22	Janssen Vaccines & Prevention B.V.	Assays for recombinant expression systems
CA2981841A1 (en)	2015-04-14	2016-10-20	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2991002C (en)	2015-07-07	2023-11-28	Janssen Vaccines & Prevention B.V.	Vaccine against rsv
JP6840718B2 (ja)	2015-07-07	2021-03-10	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	安定化された可溶性融合前ｒｓｖｆポリペプチド
BR112018003019A2 (pt)	2015-08-20	2018-09-25	Janssen Vaccines & Prevention Bv	vacinas terapêuticas contra hpv18
US20180280519A1 (en)	2015-10-06	2018-10-04	Janssen Vaccines & Prevention B.V.	Methods for preventing plastic-induced degradation of biologicals
WO2017139392A1 (en)	2016-02-08	2017-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant hiv-1 envelope proteins and their use
EP3426291A1 (de)	2016-03-09	2019-01-16	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Rekombinante hiv-1-hüllproteine und deren verwendung
KR102500970B1 (ko)	2016-04-05	2023-02-17	얀센 백신스 앤드 프리벤션 비.브이.	Rsv에 대한 백신
PT3439672T (pt)	2016-04-05	2021-02-24	Janssen Vaccines & Prevention Bv	Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
MX2018013340A (es)	2016-05-02	2019-08-21	Janssen Vaccines & Prevention Bv	Combinaciones de vacunas terapeuticas para el vph.
KR102421049B1 (ko)	2016-05-30	2022-07-15	얀센 백신스 앤드 프리벤션 비.브이.	안정화된 융합-전 rsv f 단백질
CN109312362B (zh)	2016-06-20	2022-06-28	扬森疫苗与预防公司	有效和平衡的双向启动子
US10744196B2 (en)	2016-07-14	2020-08-18	Janssen Vaccines & Prevention B.V.	HPV vaccines
CA3038968A1 (en)	2016-09-30	2018-04-05	Genvec, Inc.	Adenovectors for delivery of therapeutic genetic material into t cells
US11602559B2 (en)	2016-10-03	2023-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	HIV-1 Env fusion peptide immunogens and their use
EP4599847A3 (de)	2016-10-25	2025-11-12	Trustees of Dartmouth College	Präfusionscoronavirus-spike-proteine und deren verwendung
WO2018109220A2 (en)	2016-12-16	2018-06-21	Institute For Research In Biomedicine	Novel recombinant prefusion rsv f proteins and uses thereof
SG11201906271QA (en)	2017-02-09	2019-08-27	Janssen Vaccines & Prevention Bv	Potent and short promoter for expression of heterologous genes
US11235056B2 (en)	2017-03-24	2022-02-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Glycan-masked engineered outer domains of HIV-1 gp120 and their use
TW201907937A (zh)	2017-05-08	2019-03-01	美商葛利史東腫瘤科技公司	阿爾法病毒新抗原載體
JP2020519663A (ja)	2017-05-17	2020-07-02	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
US11229695B2 (en)	2017-09-15	2022-01-25	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against RSV
EP3697440A1 (de)	2017-10-16	2020-08-26	The United States of America, as represented by the Secretary, Department of Health and Human Services	Rekombinante hiv-1-hüllproteine und deren verwendung
EP3704139A1 (de)	2017-10-31	2020-09-09	Janssen Vaccines & Prevention B.V.	Adenovirus und verwendungen davon
SG11202003200VA (en)	2017-10-31	2020-05-28	Janssen Vaccines & Prevention Bv	Adenovirus and uses thereof
JP7366014B2 (ja)	2017-10-31	2023-10-20	ヤンセンファッシンズアンドプリベンションベーフェー	アデノウイルス及びその用途
EP3704256A1 (de)	2017-10-31	2020-09-09	Janssen Vaccines & Prevention B.V.	Adenovirus-vektoren und verwendungen davon
PT3743106T (pt)	2018-01-23	2022-08-24	Janssen Vaccines & Prevention Bv	Vacinas contra o vírus da influenza e suas utilizações
IL277128B2 (en)	2018-03-06	2025-11-01	Precigen Inc	Hepatitis b vaccines and uses of the same
US12404306B2 (en)	2018-03-06	2025-09-02	Precigen, Inc.	Human papillomavirus vaccines and uses of the same
AU2019368218B2 (en)	2018-10-22	2026-02-12	New York University	Recombinant GP120 protein with V1-loop deletion
CN113164583A (zh)	2018-11-13	2021-07-23	扬森疫苗与预防公司	稳定的融合前rsv f蛋白
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
MX2021012991A (es)	2019-04-25	2021-12-10	Janssen Vaccines & Prevention Bv	Antigenos de gripe recombinantes.
US20220193219A1 (en)	2019-05-15	2022-06-23	Janssen Vaccines & Prevention B.V.	Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
EP3969044A1 (de)	2019-05-15	2022-03-23	Janssen Vaccines & Prevention B.V.	Gleichzeitige verabreichung eines saisonalen grippeimpfstoffs und eines adenovirus-basierten impfstoffs gegen das respiratorische synzytialvirus
MX2021014525A (es) *	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
CA3152957A1 (en)	2019-09-05	2021-03-11	Janssen Vaccines & Prevention B.V.	Influenza virus vaccines and uses thereof
JP7711050B2 (ja)	2019-10-03	2025-07-22	ヤンセンファッシンズアンドプリベンションベーフェー	アデノウイルスベクターおよびその使用
JP7640538B2 (ja)	2019-10-08	2025-03-05	トラスティーズオブボストンカレッジ	複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
CN114980920A (zh)	2019-11-18	2022-08-30	詹森生物科技公司	基于突变体calr和jak2的疫苗及其用途
CN114981298B (zh)	2019-12-12	2024-08-20	听治疗有限责任公司	用于预防和治疗听力损失的组合物和方法
MX2022009836A (es)	2020-02-11	2022-11-30	Us Health	Vacuna para sars-cov-2.
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
AU2021357520A1 (en)	2020-03-05	2022-09-29	Neotx Therapeutics Ltd.	Methods and compositions for treating cancer with immune cells
US11773391B2 (en)	2020-04-01	2023-10-03	University of Pittsburgh—of the Commonwealth System of Higher Education	Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
EP4135757A1 (de)	2020-04-13	2023-02-22	Janssen Biotech, Inc.	Psma- und steap1-impfstoffe und ihre verwendungen
EP4142785A2 (de)	2020-04-29	2023-03-08	The United States of America, as represented by the Secretary, Department of Health and Human Services	Rekombinante menschliche metapneumovirus f proteine und deren verwendung
WO2022009052A2 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
US20230024133A1 (en)	2020-07-06	2023-01-26	Janssen Biotech, Inc.	Prostate Neoantigens And Their Uses
WO2022009051A1 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	A method for determining responsiveness to prostate cancer treatment
WO2022035860A2 (en)	2020-08-10	2022-02-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Replication-competent adenovirus type 4-hiv env vaccines and their use
US20240228549A1 (en)	2021-04-29	2024-07-11	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Prefusion-stabilized lassa virus glycoprotein complex and its use
AU2022323509A1 (en)	2021-08-03	2024-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250018060A1 (en)	2021-11-19	2025-01-16	Christiana Care Gene Editing Institute, Inc.	Adenovirus delivery system for cancer treatment
WO2023192835A1 (en)	2022-03-27	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en)	2022-04-07	2023-10-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Beta globin mimetic peptides and their use
EP4338727A1 (de)	2022-09-14	2024-03-20	Roquette Freres	Adenovirus-formulierungen
WO2024233783A1 (en)	2023-05-09	2024-11-14	Cornell University	Expression cassette coding for vascular endothelial growth factor
WO2024249626A1 (en)	2023-05-30	2024-12-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 envelope triple tandem trimers and their use
WO2025158316A1 (en)	2024-01-26	2025-07-31	Janssen Biotech, Inc.	Ovarian neoantigens and use thereof
WO2026030724A1 (en)	2024-08-01	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Sars-cov-2 vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4405712A (en) *	1981-07-01	1983-09-20	The United States Of America As Represented By The Department Of Health And Human Services	LTR-Vectors
US5585362A (en) *	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
JPH08501686A (ja) *	1992-09-25	1996-02-27	ローン−プーラン・ロレ・ソシエテ・アノニム	中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
WO1994011506A1 (en) *	1992-11-18	1994-05-26	Arch Development Corporation	Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
JPH08503855A (ja) *	1992-12-03	1996-04-30	ジェンザイム・コーポレイション	嚢胞性線維症に対する遺伝子治療
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE304604T1 (de) *	1993-06-24	2005-09-15	Frank L Graham	Adenovirus vektoren für gentherapie
CN1115414C (zh) *	1993-07-13	2003-07-23	罗纳-布朗克罗莱尔股份有限公司	用于基因治疗的病毒载体
FR2707664B1 (fr) *	1993-07-13	1995-09-29	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
LU88429A1 (fr) *	1993-11-23	1995-07-10	Wurth Paul Sa	Dispositif de chargement d'un four à cuve
US5731172A (en) *	1994-03-09	1998-03-24	Sumitomo Pharmaceuticals Company, Ltd.	Recombinant adenovirus and process for producing the same
US5872005A (en) *	1994-11-03	1999-02-16	Cell Genesys Inc.	Packaging cell lines for adeno-associated viral vectors

1995
- 1995-12-14 US US08/572,126 patent/US5851806A/en not_active Expired - Lifetime
1996
- 1996-12-12 EP EP96944346A patent/EP0870049B1/de not_active Expired - Lifetime
- 1996-12-12 CA CA002238295A patent/CA2238295C/en not_active Expired - Lifetime
- 1996-12-12 DE DE69635931T patent/DE69635931T2/de not_active Expired - Lifetime
- 1996-12-12 IL IL12479796A patent/IL124797A0/xx unknown
- 1996-12-12 GE GEAP19964402A patent/GEP20012559B/en unknown
- 1996-12-12 HU HU9902310A patent/HUP9902310A3/hu unknown
- 1996-12-12 JP JP52221897A patent/JP3299761B2/ja not_active Expired - Lifetime
- 1996-12-12 EE EE9800185A patent/EE9800185A/xx unknown
- 1996-12-12 WO PCT/US1996/019839 patent/WO1997021826A2/en not_active Ceased
- 1996-12-12 BR BR9612677A patent/BR9612677A/pt not_active Application Discontinuation
- 1996-12-12 SK SK785-98A patent/SK78598A3/sk unknown
- 1996-12-12 AU AU14177/97A patent/AU711366B2/en not_active Ceased
- 1996-12-12 EA EA199800566A patent/EA199800566A1/ru unknown
- 1996-12-12 CZ CZ981827A patent/CZ182798A3/cs unknown
- 1996-12-12 AT AT96944346T patent/ATE320503T1/de not_active IP Right Cessation
- 1996-12-12 PL PL96327984A patent/PL327984A1/xx unknown
- 1996-12-12 NZ NZ325627A patent/NZ325627A/xx unknown
1998
- 1998-06-03 IS IS4762A patent/IS4762A/is unknown
- 1998-06-11 NO NO982687A patent/NO982687L/no not_active Application Discontinuation
- 1998-07-08 BG BG102612A patent/BG62739B1/bg unknown
2001
- 2001-12-25 JP JP2001392883A patent/JP2002199894A/ja active Pending

Also Published As

Publication number	Publication date
JP3299761B2 (ja)	2002-07-08
EA199800566A1 (ru)	1999-02-25
ATE320503T1 (de)	2006-04-15
DE69635931T2 (de)	2006-11-30
IL124797A0 (en)	1999-01-26
EE9800185A (et)	1998-12-15
WO1997021826A2 (en)	1997-06-19
GEP20012559B (en)	2001-10-25
NZ325627A (en)	2000-01-28
JPH11502421A (ja)	1999-03-02
CZ182798A3 (cs)	1998-11-11
BR9612677A (pt)	1999-07-20
HUP9902310A2 (hu)	1999-10-28
NO982687L (no)	1998-07-13
AU711366B2 (en)	1999-10-14
HUP9902310A3 (en)	2001-11-28
US5851806A (en)	1998-12-22
JP2002199894A (ja)	2002-07-16
CA2238295C (en)	2007-04-03
AU1417797A (en)	1997-07-03
CA2238295A1 (en)	1997-06-19
NO982687D0 (no)	1998-06-11
EP0870049B1 (de)	2006-03-15
EP0870049A2 (de)	1998-10-14
DE69635931D1 (de)	2006-05-11
BG62739B1 (bg)	2000-06-30
WO1997021826A3 (en)	1997-09-12
MX9804716A (es)	1998-10-31
PL327984A1 (en)	1999-01-04
BG102612A (en)	1999-04-30
IS4762A (is)	1998-06-03

Publication	Publication Date	Title
EP0870049B1 (de)	2006-03-15	Komplementäre adenovirenvektorsysteme und zellinien
EP0784690B1 (de)	2006-08-16	Adenoviren-vektor systeme und zelllinien
EP0988389B1 (de)	2006-05-10	Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind
US5837511A (en)	1998-11-17	Non-group C adenoviral vectors
CN100374574C (zh)	2008-03-12	稳定的腺病毒载体及其增殖方法
CA2378061A1 (en)	2001-01-25	Packaging systems for human recombinant adenovirus to be used in gene therapy
AU730278B2 (en)	2001-03-01	Complementary adenoviral vector systems and cell lines
AU703768C (en)	2000-04-06	Complementary adenoviral vector systems and cell lines
MXPA98004716A (en)	1999-01-11	Complementary systems of adenoviral vectors and cell lines